A Different Approach, A New Cancer Drug... Dr. Paul Lammers, CEO Triumvira Immunologics

Cancer treatments which work with the immune system are making great strides, with Keytruda from Merck being perhaps the best known. Still there is much work to be done – both in developing unprecedented new treatments, as well as treatments which might combine with our existing treatments to make them even more effective. Triumvera (try-um-VEERA) Immunologics is working on both. Dr. Paul Lammers is its CEO.